NDOIEndo, Inc.

About Endo, Inc. (NDOI)

Endo, Inc. (NDOI) is a Drug Manufacturers - Specialty & Generic company headquartered in Malvern, PA, United States whose shares trade over-the-counter on the OTCQX tier.

Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Endo develops, manufactures, markets and sells a broad portfolio of pharmaceutical products across four reportable segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Endo, Inc. was formed in December 2023 to facilitate the acquisition of substantially all of the assets of Endo International plc. Upon effectiveness of the plan of reorganization, Endo International plc's operating assets exited the Chapter 11 financial restructuring process with significantly reduced outstanding indebtedness and resolution of Endo International plc's pre-bankruptcy litigation overhang. Our predecessor company, Endo International plc, was incorporated in Ireland in 2013, but Endo's history can be traced back to the early 20th century. Endo International plc initiated a financial restructuring process in 2022, with a goal of emerging as a strong growth company.

Products and services

Our Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. The Sterile Injectables provides critical medicines that are trusted by essentially every hospital system. Our Generics Pharmaceuticals segment provides high-quality, low-cost medicines and out International segment provides innovative medicines for the Canadian market. Our core areas of growth include the Specialty Products portfolio within our Branded Pharmaceuticals segment and our Sterile Injectables segment. The Specialty Products portfolio is primarily focused on non-surgical treatment options for conditions treated by urologists, orthopedic surgeons and other specialists. The Sterile Injectables portfolio is focused on ready-to-use and differentiated products which are primarily used in hospital settings. We believe these product portfolios provide the greatest opportunity for us to generate durable revenue and cash flow growth.

NDOI key facts

Ticker symbol

NDOI

Market tier

OTCQX

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Malvern, PA, United States

Country of incorporation

US

Year of incorporation

2023

Employees

2,995

Estimated market cap

$1.71B (as of Apr 9, 2025)

Shares outstanding

76,211,329

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Endo, Inc. leadership

• Scott Hirsch — Interim CEO
• Mark T. Bradley — EVP, CFO
• Patrick A. Barry — EVP, President
• Matthew J. Maletta — EVP, CLO , Secretary
• James P. Tursi — EVP
• Laure Park — SVP, Inv. Rel.
• Brian Morrissey — Corporate Counsel, Asst. Secretary
• Deanna Voss — Asst. Secretary

Explore more: Drug Manufacturers - Specialty & Generic stocks · Healthcare sector · OTCQX stocks · OTC stocks starting with N